This morning, Roche announced that the Food and Drug Administration refused to consider the application for the TDM-1 breast cancer drug based on technology that it licensed from Immunogen, a Waltham, Mass. biotechnology company.

FORBES: Bad News For Immunogen

One of his success stories is 57-year-old breast-cancer surgeon Robert DerHagopian, who started injecting growth hormone a year ago to regain the muscle mass he lost after undergoing surgery for a perforated colon.

FORBES: Sweet Syringe of Youth

One of his success stories is a 57-year-old breast-cancer surgeon, Robert DerHagopian, who started injecting growth hormone a year ago to regain the muscle mass he lost after undergoing surgery for a perforated colon.

FORBES: Sweet syringe of youth